Debrisoquine hydroxylase (CYP2D6) and prostate cancer.


Journal Article

The p450 hepatic microsomal enzyme system metabolizes exogenous drugs and carcinogens. Debrisoquine hydroxylase (CYP2D6), one member of the p450 hemoproteins, has polymorphic expression leading to poor metabolism of debrisoquine and similar compounds in approximately 7% of Caucasians. The genetic locus for this enzyme has been characterized, and the mutations responsible for the slowed metabolism have been identified. Epidemiological studies of the CYP2D6 phenotype suggest an association between the normal or rapid metabolism phenotype and increased risk of lung and bladder cancer. Preliminary data have also suggested an association with prostate cancer (CaP). We used a PCR-based assay to investigate possible associations between the CYP2D6 B allele, the most common genetic mutation responsible for the poor metabolism phenotype, and CaP. Using genomic DNA isolated from peripheral blood, we genetically typed 571 men with CaP and 767 matched controls, all participants in the Physician's Health Study. Relative to men homozygous for the wild-type allele, heterozygotes for the B allele have an odds ratio of 1.19 (95% confidence interval, 0.94-1.51) for CaP, and men homozygous for the B allele have an odds ratio of 1.37 (95% confidence interval, 0.86-2.20). When analyzed as a trend over zero, one, or two copies of the B allele, there emerges a possible association between the B allele and an increased risk of CaP of borderline statistical significance (P = 0.07).

Full Text

Cited Authors

  • Febbo, PG; Kantoff, PW; Giovannucci, E; Brown, M; Chang, G; Hennekens, CH; Stampfer, M

Published Date

  • December 1998

Published In

Volume / Issue

  • 7 / 12

Start / End Page

  • 1075 - 1078

PubMed ID

  • 9865424

Pubmed Central ID

  • 9865424

International Standard Serial Number (ISSN)

  • 1055-9965


  • eng

Conference Location

  • United States